Drugs / RP-3467
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06560632 | Sep 2024 → Oct 2025 | neoplasm | Repare Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-3467 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06560632 ↗ |
| Action | Inhibit | “Polθ inhibitor RP-3467” NCT06560632 ↗ |
| Route | Oral | “RP-3467 when administered orally” NCT06560632 ↗ |